New hope for transplant patients: simpler drug combo may reduce severe side effects

NCT ID NCT06252870

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 6 times

Summary

This study tests two different pre-transplant chemotherapy plans combined with a single drug (cyclophosphamide) given after transplant to prevent graft-versus-host disease (GVHD), a common and serious complication. About 82 adults with blood cancers who have a matched donor will participate. The goal is to see if this simpler approach can reduce severe GVHD while improving recovery and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU Angers
RECRUITING

Angers, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
CHU Brest
RECRUITING

Brest, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
CHU Nantes
RECRUITING

Nantes, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GRAFT VERSUS HOST DISEASE HEMATOLOGIC MALIGNANCY HEMATOLOGIC MALIGNANCY